# A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer

> **NCT02591095** · PHASE2 · COMPLETED · sponsor: **Centre Francois Baclesse** · enrollment: 47 (actual)

## Conditions studied

- Platinum-resistant or Refractory Ovarian Cancer

## Interventions

- **DRUG:** ABT-263

## Key facts

- **NCT ID:** NCT02591095
- **Lead sponsor:** Centre Francois Baclesse
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2017-04
- **Final completion:** 2019-03
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2019-03-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02591095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02591095, "A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02591095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*